ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

TPST Tempest Therpeutics Inc

2.9001
-0.1299 (-4.29%)
15 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Tempest Therpeutics Inc NASDAQ:TPST NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.1299 -4.29% 2.9001 2.75 4.61 3.10 2.84 3.10 569,225 05:00:03

Tempest to Present at the H.C. Wainwright 25th Annual Global Investment Conference

05/09/2023 1:00pm

GlobeNewswire Inc.


Tempest Therpeutics (NASDAQ:TPST)
Historical Stock Chart


From Jun 2023 to Jun 2024

Click Here for more Tempest Therpeutics Charts.

Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-classi therapeutics that combine both targeted and immune-mediated mechanisms, announced today that Sam Whiting, M.D., Ph.D., chief medical officer of Tempest, will present at the H.C. Wainwright 25th Annual Global Investment Conference.

The company presentation will be available for on-demand viewing Monday, September 11, 2023, at 7:00 a.m. ET on the investor section of the Tempest website at https://ir.tempesttx.com.

About Tempest Therapeutics

Tempest Therapeutics is a clinical-stage oncology company advancing small molecules that combine both tumor-targeted and immune-mediated mechanisms with the potential to treat a wide range of tumors. The company has a diverse portfolio of novel programs ranging from early research to investigation in a randomized global study in first-line cancer patients. The company’s two clinical programs, TPST-1120 and TPST-1495, target PPARα and EP2/EP4, respectively, and are advancing through trials designed to study the agents as monotherapies and in combination with approved agents. TPST-1120 is currently being evaluated in first line hepatocellular carcinoma (HCC) in combination with atezolizumab and bevacizumab, the standard of care for first-line HCC, in a Phase 1b/2 randomized global study where an early data cut demonstrated positive results in multiple categories; the company expects the formal data set in the second half of 2023. TPST-1495 is being evaluated in combination with pembrolizumab in a Phase 1b expansion cohort in patients with advanced endometrial cancer. Tempest is also developing an orally available inhibitor of TREX1, a target that controls activation of the cGAS/STING pathway. Tempest is headquartered in Brisbane, California. More information about Tempest can be found on the company’s website at www.tempesttx.com.

Investor Contacts:

Sylvia WheelerWheelhouse Life Science Advisorsswheeler@wheelhouselsa.com 

Aljanae Reynolds Wheelhouse Life Science Advisorsareynolds@wheelhouselsa.com 

________________________i If approved by the FDA

1 Year Tempest Therpeutics Chart

1 Year Tempest Therpeutics Chart

1 Month Tempest Therpeutics Chart

1 Month Tempest Therpeutics Chart

Your Recent History

Delayed Upgrade Clock